AGM/EGMJun 11, 2026, 06:51 AM
Pharvaris Schedules Annual General Meeting for June 26
AI Summary
Pharvaris N.V. announced that its Annual General Meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST. All relevant documents and information for the meeting are or will be made available in the "Investors" section of the company's website and on the SEC's website. Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for conditions like hereditary angioedema, with topline data for its CHAPTER-3 Phase 3 study anticipated in Q3 2026.
Key Highlights
- Annual General Meeting scheduled for Friday, June 26, 2026.
- Meeting to be held at 16:00 CEST (10:00 a.m. EDT).
- Relevant documents available in the "Investors" section of Pharvaris' website.
- Documents also accessible on the SEC's website.
- Pharvaris develops oral bradykinin B2 receptor antagonists for angioedema.
- CHAPTER-3 Phase 3 study topline data anticipated in Q3 2026.
- CREAATE is an ongoing Phase 3 study for AAE-C1INH attacks.
Price Impact
More from PHVS